The Pseudomonas aeruginosa quorum-sensing molecule N-3-(oxododecanoyl)-L-homoserine lactone inhibits T-cell differentiation and cytokine production by a mechanism involving an early step in T-cell activation.
The Pseudomonas aeruginosa quorum-sensing molecule N-3-(oxododecanoyl)-L-homoserine lactone (OdDHL) has been reported to have immunomodulatory activity in several systems, although the mechanism of that activity remains to be fully characterized. We demonstrate here, using a defined in vitro model of antigen responses by T-cell receptor (TCR)-transgenic mouse splenic CD4 T cells, that the effect of OdDHL on activation and cytokine production is complete within 4 h of antigen or mitogen stimulation and does not depend on the insertion of OdDHL in the cell membrane, despite a previous report that immunosuppression by homoserine lactones required a minimum acyl chain length of 11 carbons (S. R. Chhabra, C. Harty, D. S. W. Hooi, M. Daykin, B. W. Bycroft, P. Williams, and D. Pritchard, J. Med. Chem. 46:97-104, 2003). We also demonstrate that while OdDHL can have toxic effects on nonlymphoid leukocytes, it does not induce significant cell death in T cells at the concentrations (< or =10 microM) used in these experiments. In addition, we show that primary and secondary antigen-specific cytokine responses are equally susceptible to inhibition by OdDHL and that the compound inhibits the differentiation of both Th1 and Th2 cells. However, the precise balance of cytokine production by CD4 T cells stimulated in the presence of OdDHL varies with both the antigen concentration and its affinity for the transgenic TCR. Thus, conflicting reports of the nature of the immunosuppression by OdDHL may be due in part to the differences in antigen affinity and concentration in different models.
Ritchie
A J
AJ
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
Jansson
A
A
Stallberg
J
J
Nilsson
P
P
Lysaght
P
P
Cooley
M A
MA
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D030801:Animals, Genetically Modified; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis*; D019672:Genes, T-Cell Receptor; D006714:Homoserine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D051379:Mice; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000378:metabolism*; D015398:Signal Transduction; D013047:Specific Pathogen-Free Organisms; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000276:immunology
D016207:Cytokines; C109860:N-(3-oxododecanoyl)homoserine lactone; D006714:Homoserine; D015107:4-Butyrolactone
Br J Pharmacol. 1999 Oct;128(4):845-8
10556916
J Immunol. 1999 Aug 1;163(3):1205-13
10415015
J Immunol. 2001 Jul 1;167(1):366-74
11418672
Br J Pharmacol. 2001 Aug;133(7):1047-54
11487515
J Bacteriol. 2002 Feb;184(4):1132-9
11807074
J Immunol. 2002 Sep 1;169(5):2636-42
12193735
Infect Immun. 2002 Oct;70(10):5635-46
12228292
J Med Chem. 2003 Jan 2;46(1):97-104
12502363
Infect Immun. 2003 Aug;71(8):4421-31
12874321
Infect Immun. 2003 Oct;71(10):5785-93
14500500
Immunobiology. 2003;208(4):401-11
14748513
J Bacteriol. 2004 Apr;186(8):2281-7
15060029
J Immunol. 1986 Apr 1;136(7):2348-57
2419430
Mol Cell Biol. 1988 Dec;8(12):5459-69
3266655
J Clin Invest. 1995 Nov;96(5):2204-10
7593606
J Bacteriol. 1996 Jan;178(2):435-40
8550463
Infect Immun. 1997 Feb;65(2):617-22
9009321
Annu Rev Immunol. 1997;15:297-322
9143690
Infect Immun. 1998 Jan;66(1):36-42
9423836
Annu Rev Immunol. 1999;17:149-87
10358756
J Microbiol Methods. 2001 Apr;44(3):239-51
11240047